These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11296620)

  • 1. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations.
    Perez EA
    Cancer Invest; 2001; 19(2):155-64. PubMed ID: 11296620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
    Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer.
    Moreira A; Lobato R; Morais J; Silva S; Ribeiro J; Figueira A; Vale D; Sousa C; Araújo F; Fernandes A; Oliveira J; Passos-Coelho JL
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):333-7. PubMed ID: 11710635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
    Sparano JA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):14-9. PubMed ID: 10426454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
    Gianni L; Munzone E; Capri G; Fulfaro F; Tarenzi E; Villani F; Spreafico C; Laffranchi A; Caraceni A; Martini C
    J Clin Oncol; 1995 Nov; 13(11):2688-99. PubMed ID: 7595726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
    Holmes FA
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
    Panday VR; ten Bokkel Huinink WW; Rosing H; Koopman FJ; Hillebrand MJ; Dubbelman RC; van Tellingen O; Schellens JH; Beijnen JH
    Anticancer Drugs; 1998 Sep; 9(8):665-73. PubMed ID: 9823424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
    Sparano JA; Speyer J; Gradishar WJ; Liebes L; Sridhara R; Mendoza S; Fry D; Egorin MJ
    J Clin Oncol; 1999 Mar; 17(3):880-6. PubMed ID: 10071279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.
    Gianni L; Dombernowsky P; Sledge G; Martin M; Amadori D; Arbuck SG; Ravdin P; Brown M; Messina M; Tuck D; Weil C; Winograd B
    Ann Oncol; 2001 Aug; 12(8):1067-73. PubMed ID: 11583187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
    Danesi R; Conte PF; Del Tacca M
    Clin Pharmacokinet; 1999 Sep; 37(3):195-211. PubMed ID: 10511918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.
    Hortobagyi GN; Willey J; Rahman Z; Holmes FA; Theriault RL; Buzdar AU
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-65-S17-68. PubMed ID: 9374097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.
    Spencer CM; Faulds D
    Drugs; 1994 Nov; 48(5):794-847. PubMed ID: 7530632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Serra P; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):30-3. PubMed ID: 9144688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.
    Fisherman JS; Cowan KH; Noone M; Denicoff A; Berg S; Poplack D; Balis F; Venzon D; McCabe M; Goldspiel B; Chow C; Ognibene FP; O'Shaughnessy J
    J Clin Oncol; 1996 Mar; 14(3):774-82. PubMed ID: 8622023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
    Buzdar AU; Holmes FA; Hortobagyi GN
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):101-4. PubMed ID: 7541151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.